154 results on '"Yoshizawa, Carl"'
Search Results
2. Supplementary Legend from Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer
3. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong
4. Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer
5. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
6. Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
7. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
8. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
9. MP45-14 COMPARISON OF DIFFERENT ANALYTICAL PLATFORMS FOR THE IDENTIFICATION OF TUMOR DNA IN THE URINE OF BLADDER CANCER PATIENTS
10. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital
11. Smoking History and Survival among Lung Cancer Patients
12. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
13. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial
14. Pharmacokinetics of Recombinant Human Interferon-βser in Healthy Volunteers and Its Effect on Serum Neopterin
15. Prospective study of alcohol intake and large bowel cancer
16. Pharmacokinetics and Pharmacodynamics of Recombinant FGF-2 in a Phase I Trial in Coronary Artery Disease
17. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4 + t cells
18. Do Sex Hormones Affect Colorectal Cancer?
19. Additional file 5: Figure S3. of The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
20. Additional file 2: Table S1. of The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
21. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
22. A study of the impact of the 21‐gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital
23. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
24. Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer.
25. Quantitative gene expression by RT-PCR in the tubular, cribriform, mucinous, and papillary histologic subtypes of invasive breast cancer.
26. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer
27. Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer
28. The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort.
29. Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.
30. 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
31. A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.
32. Accurate Assessment of Human Epidermal Growth Factor Receptor 2
33. Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
34. Ethnic patterns of childhood cancer in Hawaii between 1960 and 1984
35. Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features
36. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ t cells
37. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
38. Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
39. Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer.
40. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
41. Dietary factors in lung cancer prognosis
42. Covariance adjustment of survival curves based on Cox′s proportional hazards regression model
43. Dietary factors in cancer of the lower urinary tract
44. Validation of a Quantitative Diet History Method in Hawaii
45. Lifetime Occupational Physical Activity and Prostate Cancer Risk
46. Reproducibility of a diet history in older men in Hawaii
47. Descriptive epidemiology of thyroid cancer in Hawaii.
48. Comparison of Long-Term Dietary Recall between Cancer Cases and Noncases.
49. SMOKING, ALCOHOL, OCCUPATION, AND HAIR DYE USE IN CANCER OF THE LOWER URINARY TRACT.
50. THE EFFECT OF DIETARY CHOLESTEROL AND FAT ON THE RISK OF LUNG CANCER IN HAWAII1.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.